Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## 溫州康寧醫院股份有限公司 Wenzhou Kangning Hospital Co., Ltd.

(A joint stock limited liability company incorporated in the People's Republic of China) Stock code: 2120

## VOLUNTARY ANNOUNCEMENT PRINCIPAL OPERATING DATA AND INDICATORS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2024 AND THE THIRD QUARTER 2024

This is a voluntary announcement made by Wenzhou Kangning Hospital Co., Ltd. (the "Company") to keep the shareholders of the Company and potential investors informed of the latest business developments of the Company and its subsidiaries (the "Group").

The table below sets forth the relevant operating data and indicators of the Group's owned hospitals by inpatients and outpatients for the nine months ended September 30, 2024 with comparative figures for the nine months ended September 30, 2023:

	For the nine months ended September 30,		Year- on-year
	2024	2023	changes
Inpatients			
Number of inpatient bed-days	2,838,582	2,533,506	12.0%
Average inpatient spending per bed-day on treatment and general healthcare services (RMB)	318	338	-5.9%
Average inpatient spending per bed-day on pharmaceutical sales (RMB)	49	51	-3.9%
Total average inpatient spending per bed-day (RMB) <sup>(1)</sup>	367	389	-5.7%
Outpatients			
Number of outpatient visits	369,309	378,718	-2.5%
Average outpatient spending per visit on treatment and general healthcare services (RMB)	128	135	-5.2%
Average outpatient spending per visit on pharmaceutical sales (RMB)	305	292	4.5%
Total average outpatient spending per visit (RMB)	433	427	1.4%

The table below sets forth the relevant operating data and indicators of the Group's owned hospitals by inpatients and outpatients for the three months (the third quarter) from July 1, 2024 to September 30, 2024 with comparative figures of the same period in 2023:

	Three months from July 1 to September 30, 2024 2023		Year- on-year changes
Inpatients			
Number of inpatient bed-days	986,185	926,084	6.5%
Average inpatient spending per bed-day on treatment and general healthcare services ( <i>RMB</i> )  Average inpatient spending per bed-day on	320	327	-2.1%
pharmaceutical sales (RMB)	48	48	0.0%
Total average inpatient spending per bed-day $(RMB)^{(1)}$	369	375	-1.6%
Outpatients			
Number of outpatient visits	126,201	128,070	-1.5%
Average outpatient spending per visit on treatment and general healthcare services (RMB)  Average outpatient spending per visit on	125	137	-8.8%
pharmaceutical sales (RMB)	290	296	-2.0%
Total average outpatient spending per visit (RMB)	415	433	4.2%

## Note:

1. The above total average inpatient spending per bed-day is determined based on the Company's bills for services provided to patients, without taking into account differences with medical insurance settlements and the Company's income deduction for some medical expenses that may not be received.

The above operating data and indicators are based on the Company's records and have not been audited or reviewed by the Company's auditors. The operating data and indicators may be different from those disclosed in relevant periodical reports. The operating data and indicators disclosed in relevant periodical reports shall prevail if there is any discrepancy.

Shareholders and potential investors of the Company are reminded to rationally deal with any information not officially released by the Company, and shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

By order of the Board
Wenzhou Kangning Hospital Co., Ltd.
GUAN Weili
Chairman

Zhejiang, the PRC October 3, 2024

As at the date of this announcement, the Company's executive directors are Mr. GUAN Weili, Ms. WANG Lianyue and Mr. WANG Jian; the non-executive directors are Mr. QIN Hao and Mr. LI Changhao; and the independent non-executive directors are Ms. ZHONG Wentang, Ms. JIN Ling and Mr. CHAN Sai Keung Hugo.